What happens when politics collides head-on with monetary policy? On this episode of In the Money with Amber Kanwar, Amber sits down with legendary Fed watcher Ed Yardeni, President of Yardeni Research, to unpack what he calls an unprecedented threat to the independence of the U.S. Federal Reserve — and why the market may be more resilient than the headlines suggest.
Pro Picks is brought to you by ATB Financial. With $62 billion in assets, ATB Financial is powering possibilities for more than 820,000 financial services clients in Alberta and beyond. ATB’s Capital Markets arm is a full-service investment dealer that offers investment and corporate banking, sales and trading, institutional research, and risk management. Visit www.ATB.com/inthemoney for more information.
- Increased competition in the AI space has turned these companies into rivals, eroding their once-isolated “moats” as they invade each other’s businesses in an arms race.
- Massive capital spending on AI infrastructure lacks clear returns on investment, with risks of obsolescence if cheaper, more efficient chips emerge from Nvidia or competitors.
- The true beneficiaries of AI will be the S&P 493 companies that adopt these tools to boost productivity, signaling a market broadening beyond the Magnificent 7’s dominance.
Overweight Gold
- Central banks have ramped up gold purchases since Russia’s invasion of Ukraine and the freezing of reserves, providing a strong demand floor.
- Chinese investors, battered by property market collapses and stock volatility, are flocking to gold as a reliable asset that consistently appreciates.
- Technical analysis shows a rapid upward channel, with Yardeni raising his year-end target to $6,000 per ounce, reflecting momentum in the entire precious metals complex.
Overweight Healthcare
- The sector offers compelling characteristics like earnings growth, high dividends, and low valuations, making it a standout in a market seeking balance.
- Pharmaceutical companies face drying pipelines, spurring an M&A boom with biotech startups that promise breakthroughs in cures and treatments.
- Early-stage consolidation in biotech will benefit big pharma through leveraged innovations, with a positive earnings outlook overriding political controversies around policies like Obamacare.
Don’t miss our next episode!
DISCLAIMERS: This text AI generated, human edited. The information provided in this podcast is for informational purposes only and does not constitute financial, investment, or professional advice. The views expressed by the host and guests are their own and do not necessarily reflect the opinions of any organization or company. The host and guests may maintain positions in any securities discussed on the podcast. Always consult with a qualified financial advisor or professional before making any investment decisions.
